Highlights from

American Society of Hematology

Annual meeting 2018

SCROLL TO ARTICLES

CASSINI: Rivaroxaban demonstrates thromboprophylactic efficacy in high-risk ambulatory patients with cancer

BELIEVE: Luspatercept significantly reduces transfusion burden versus placebo in patients with beta-thalassaemia

TITAN and HERCULES: Caplacizumab - a new treatment option for patients with life-threatening aTTP?

MAIA: Daratumumab with lenalidomide plus dexamethasone for the treatment of transplant-ineligible, newly diagnosed multiple myeloma

Alliance: Ibrutinib demonstrates superior PFS to standard CIT in treatment-naive patients aged ≥65 with CLL

SPIRIT 2: 5-year data released from the largest (n=814) study of imatinib and dasatinib in newly diagnosed CML

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

Supported by